长链非编码RNA在结直肠癌中的作用

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (2): 222-227.

长链非编码RNA在结直肠癌中的作用

孙跃胜¹，屈强²，潘江华¹，童晓春¹，陈恩德¹，屈健³

¹温州医科大学温州市第三临床学院，温州市人民医院普外科，温州 325000，浙江；²中南大学湘雅医院药剂科，长沙 410078，湖南；³中南大学湘雅二医院药剂科，中南大学临床药学研究所，长沙 410011，湖南

收稿日期:2016-11-22 修回日期:2017-01-08 出版日期:2017-02-26 发布日期:2017-03-02
通讯作者: 屈健，男，博士，药师，研究方向：遗传药理学。 Tel：0731-85292128 E-mail：qujianstanley@163.com
作者简介:孙跃胜，男，本科，主治医师，研究方向：结直肠癌。 Tel：13506668651 E-mail：sunys1982@163.com
基金资助:
国家自然科学基金（81503166, 81603208）；中南大学湘雅医院青年科研基金（2014Q08）

Role of lncRNAs in colorectal cancer

SUN Yuesheng ¹, QU Qiang², PAN Jianghua ¹, TONG Xiaochun¹, CHEN Ende¹, QU Jian ³

¹ Department of General Surgery, the Third Clinical College of Wenzhou Medical University, Wenzhou People's Hospital, Wenzhou 325000, Zhejiang, China; ²Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410078, Hunan, China; ³ Department of Pharmacy, the Second Xiangya Hospital, Central South University, Institute of Clinical Pharmacy, Central South University, Changsha 410011, Hunan, China

Received:2016-11-22 Revised:2017-01-08 Online:2017-02-26 Published:2017-03-02

摘要/Abstract

摘要：

长链非编码RNA（long non-coding RNA，lncRNAs）是一类长度大于200个核苷酸，不被翻译成蛋白但起着重要调控作用的RNA。近期的研究显示lncRNA在肿瘤的发生发展、转移侵袭、早期诊断、预后评价、放化疗疗效等方面起着重要作用。结直肠癌是一种常见的消化道肿瘤，其发病率和死亡率高。目前lncRNA对结直肠癌的发生发展及放化疗疗效等方面的研究取得一定进展。本文就此方面的国际最新研究进展作一综述。

关键词: 结直肠癌, 长链非编码RNA, 肿瘤

Abstract:

Long non-coding RNAs (lncRNAs) are important regulative RNAs whose length are more than 200 nucleotides and cannot be translated into protein. Recent studies have shown that lncRNAs play important roles in the tumor development, invasion and metastasis, early diagnosis, prognosis, chemo-resistance and radio-resistance of colorectal cancer (CRC). CRC is a common gastrointestinal cancer with high morbidity and mortality. Currently, there are some relevant studies on the role of lncRNAs in the development, chemor-esistance and radio-resistance of CRC. Yet this paper reviews the latest international researches in this regard.

Key words: colorectal cancer, lncRNA, tumor

中图分类号:

R968
R735

孙跃胜，屈强，潘江华，童晓春，陈恩德，屈健. 长链非编码RNA在结直肠癌中的作用[J]. 中国临床药理学与治疗学, 2017, 22(2): 222-227.

SUN Yuesheng, QU Qiang, PAN Jianghua, TONG Xiaochun, CHEN Ende, QU Jian. Role of lncRNAs in colorectal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 222-227.

参考文献

［1］Consortium EP. An integrated encyclopedia of DNA elements in the human genome［J］. Nature, 2012, 489(7414): 57-74.
［2］Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world［J］. Genes Dev, 2009, 23(13): 1494-1504.
［3］Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition［J］. Nature, 2014, 505(7483): 344-352.
［4］Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors［J］. Clin Colon Rectal Surg, 2009, 22(4): 191-197.
［5］Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition［J］. Nat Rev Mol Cell Biol, 2014, 15(3): 178-196.
［6］Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers［J］. Cancer Res, 2011, 71(20): 6320-6326.
［7］Dou J, Ni Y, He X, et al. Decreasing lncRNA HOTAIR expression inhibits human colorectal cancer stem cells［J］. Am J Transl Res, 2016, 8(1): 98-108.
［8］Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients［J］. Carcinogenesis, 2014, 35(7): 1510-1515.
［9］Wu ZH, Wang XL, Tang HM, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer［J］. Oncol Rep, 2014, 32(1): 395-402.
［10］Yang XD, Xu HT, Xu XH, et al. Knockdown of long non-coding RNA HOTAIR inhibits proliferation and invasiveness and improves radiosensitivity in colorectal cancer［J］. Oncol Rep, 2016, 35(1): 479-487.
［11］Zhao W, Song M, Zhang J, et al. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma［J］. Int J Clin Exp Pathol, 2015, 8(11): 14131-14140.
［12］Mccleland ML, Mesh K, Lorenzana E, et al. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer［J］. J Clin Invest, 2016, 126(2): 639-652.
［13］Zhai H, Fesler A, Schee K, et al. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer［J］. Clin Colorectal Cancer, 2013, 12(4): 261-266.
［14］Wang J, Lei ZJ, Guo Y, et al. miRNA-regulated delivery of lincRNA-p21 suppresses beta-catenin signaling and tumorigenicity of colorectal cancer stem cells［J］. Oncotarget, 2015, 6(35): 37852-37870.
［15］Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/beta-catenin signaling pathway［J］. Oncol Rep, 2014, 31(4): 1839-1845.
［16］Guo Q, Zhao Y, Chen J, et al. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition［J］. Oncol Lett, 2014, 8(2): 869-875.
［17］Iguchi T, Uchi R, Nambara S, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer［J］. Anticancer Res, 2015, 35(3): 1385-1388.
［18］Yue B, Qiu S, Zhao S, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis［J］. J Gastroenterol Hepatol, 2016, 31(3): 595-603.
［19］Shen F, Cai WS, Feng Z, et al. Long non-coding RNA SPRY4-IT1 pormotes colorectal cancer metastasis by regulate epithelial-mesenchymal transition［J］. Oncotarget, 2016,［Epub ahead of print］.
［20］Cao D, Ding Q, Yu W, et al. Long noncoding RNA SPRY4-IT1 promotes malignant development of colorectal cancer by targeting epithelial-mesenchymal transition［J］. Onco Targets Ther, 2016, 9: 5417-5425.
［21］Wang L, Zhao Z, Feng W, et al. Long non-coding RNA TUG1 promotes colorectal cancer metastasis via EMT pathway［J］. Oncotarget, 2016,［Epub ahead of print］.
［22］Sun J, Ding C, Yang Z, et al. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition［J］. J Transl Med, 2016, 14: 42.
［23］Han X, Wang L, Ning Y, et al. Long non-coding RNA AFAP1-AS1 facilitates tumor growth and promotes metastasis in colorectal cancer［J］. Biol Res, 2016, 49(1): 36.
［24］Li Q, Dai Y, Wang F, et al. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer［J］. Neoplasma, 2016, 63(6): 977-983.
［25］Yin D, He X, Zhang E, et al. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer［J］. Med Oncol, 2014, 31(11): 253.
［26］Kong H, Wu Y, Zhu M, et al. Long non-coding RNAs: novel prognostic biomarkers for liver metastases in patients with early stage colorectal cancer［J］. Oncotarget, 2016, ［Epub ahead of print］.
［27］Krell J, Frampton AE, Mirnezami R, et al. Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer［J］. PLoS One, 2014, 9(6): e98561.
［28］Naemura M, Tsunoda T, Inoue Y, et al. ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture［J］. Mol Cell Biochem, 2016, 412(1/2): 141-146.
［29］Sun Y, Zheng ZP, Li H, et al. ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro［J］. Mol Med Rep, 2016, 14(2): 1714-1720.
［30］Ren YK, Xiao Y, Wan XB, et al. Association of long non-coding RNA HOTTIP with progression and prognosis in colorectal cancer［J］. Int J Clin Exp Pathol, 2015, 8(9): 11458-11463.
［31］Lian Y, Ding J, Zhang Z, et al. The long noncoding RNA HOXA transcript at the distal tip promotes colorectal cancer growth partially via silencing of p21 expression［J］. Tumor Biol, 2016, 37(6): 7431-7440.
［32］Han D, Gao X, Wang M, et al. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3［J］. Oncotarget, 2016, 7(16): 22159-22173.
［33］Thorenoor N, Faltejskova-Vychytilova P, Hombach S, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer［J］. Oncotarget, 2016, 7(1): 622-637.
［34］Hu ZY, Wang XY, Guo WB, et al. Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells［J］. Oncotarget, 2016, 7(10): 11733-11743.
［35］Yang MH, Hu ZY, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9［J］. Biochim Biophys Acta, 2015, 1852(1): 166-174.
［36］Kan JY, Wu DC, Yu FJ, et al. Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1［J］. J Cell Physiol, 2015, 230(8): 1883-1894.
［37］Xu C, Yang M, Tian J, et al. MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis［J］. Int J Oncol, 2011, 39(1): 169-175.
［38］Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer［J］. Int J Clin Exp Pathol, 2014, 7(6): 3174-3181.
［39］Liang WC, Fu WM, Wong CW, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer［J］. Oncotarget, 2015, 6(26): 22513-22525.
［40］Tsang WP, Ng EK, Ng SS, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer［J］. Carcinogenesis, 2010, 31(3): 350-358.
［41］Ling H, Spizzo R, Atlasi Y, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer［J］. Genome Res, 2013, 23(9): 1446-1461.
［42］Han Y, Yang YN, Yuan HH, et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution［J］. Pathology, 2014, 46(5): 396-401.
［43］Ni B, Yu X, Guo X, et al. Increased urothelial cancer associated 1 is associated with tumor proliferation and metastasis and predicts poor prognosis in colorectal cancer［J］. Int J Oncol, 2015, 47(4): 1329-1338.
［44］Bian Z, Jin L, Zhang J, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p［J］. Sci Rep, 2016, 6: 23892.
［45］Li Y, Li Y, Chen W, et al. NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer［J］. Oncotarget, 2015, 6(29): 27641-27650.
［46］Wu Y, Yang L, Zhao J, et al. Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer［J］. Mol Cancer, 2015, 14: 191.
［47］Yin DD, Liu ZJ, Zhang E, et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer［J］. Tumor Biol, 2015, 36(6): 4851-4859.
［48］Cao X, Zhuang S, Hu Y, et al. Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese［J］. Oncotarget, 2016, 7(14): 19054-19059.
［49］Lee H, Kim C, Ku JL, et al. A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells［J］. Mol Cells, 2014, 37(7): 540-546.
［50］Liu X, Jiao T, Wang Y, et al. Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer［J］. Minerva Med, 2016,［Epub ahead of print］.
［51］Yue B, Cai D, Liu C, et al. Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer［J］. Mol Ther, 2016,［Epub ahead of print］.
［52］Ma Y, Yang Y, Wang F, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/beta-catenin signalling pathway via suppression of activator protein 2alpha［J］. Gut, 2016, 65(9): 1494-1504.

[1]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[2]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[3]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[4]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[5]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[6]	卫真真, 隋华, 姜宇朗, 孙明瑜, 闫化茹, 王子元. 左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 130-137.
[7]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[8]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.
[9]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[10]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[11]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[12]	黄好, 贾虹, 王晓霜, 张鹭, 蒋华. 负载MAGE-A3抗原的树突状细胞与细胞因子诱导杀伤细胞共培养对子宫内膜癌肿瘤干细胞及恶性进展的影响[J]. 中国临床药理学与治疗学, 2023, 28(1): 42-50.
[13]	高丽丽, 王玉珠, 王燕, 李健, 王骏. 抗肿瘤抗体偶联药物临床药理学研究的若干问题与考虑[J]. 中国临床药理学与治疗学, 2023, 28(1): 75-85.
[14]	刘佳佳, 高岩, 张业慧, 武静. CRABP2在肿瘤发生发展中的作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 86-92.
[15]	洪子强, 苟文曦, 崔百强, 白向豆, 金大成, 苟云久. m7G甲基转移酶METTL1在肿瘤中的作用[J]. 中国临床药理学与治疗学, 2023, 28(1): 93-100.